PACB (PACB) Stock Analysis
Verdict: AVOID
Contract momentum masks severe debt ($759.9M) and cash burn (<7 months runway), pointing to high dilution risk.
Investment score: 31/100
Is PACB Stock Worth Reviewing? AI Model Thesis
The model assesses PACB as an AVOID due to severe solvency risk, negative cash runway (<7 months), and a market price 100.8% above consensus target ($1.18).
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| PSNL | -14.94 | 7.30 | 24.95 | -17.30 | — | -1.54 |
| AZTA | -12.69 | 1.05 | 2.62 | -15.24 | — | -0.20 |
| CYRX | -21.22 | 1.79 | 4.70 | -268.38 | — | -0.19 |
| DNA | -2.56 | 1.90 | 7.49 | -5.54 | — | -2.60 |
| CTKB | -9.57 | 2.40 | 3.72 | -26.60 | — | -0.39 |
Should You Buy or Sell PACB Stock? Model Reasoning
While short-term commercial wins have triggered a 68.1% 5-day rally, PACB's balance sheet is severely impaired with $759.9M in debt and $63.7M in cash, representing under 7 months of operating cash runway (-$111.2M operating cash flow in 2025). Furthermore, at $2.37, the stock trades 100.8% above the consensus analyst target of $1.18, exposing buyers to sudden pullbacks or dilutive equity offerings.
PACB Fair Value & Price Target — AI Valuation
- Model Assumptions: ["PACB will be forced to execute substantial equity capital raises within 6-12 months, driving 20-40% share dilution at low valuations.","Revenue growth remains modest, reaching analyst consensus of $180M in 2027 (+12.5% over two years), leaving operating margins deeply negative (-83.5%).","Gross margins plateau in the 36-39% range, far below the scale necessary to cover $200M+ in annual operating costs."]
PACB Risk & Opportunity Analysis
Key Investment Risks
- Critical cash runway limit under 7 months — With $63.7M cash against -$111.2M annual operating cash burn, PACB will require dilutive capital raising or debt restructuring before Q3 2027.
- Overwhelming $759.9M debt burden and negative book value — Total debt of $759.9M dwarfs balance sheet equity ($5.35M in 2025), exposing the business to potential distress if revenue growth underperforms estimates ($180M in 2027).
- 100% price premium over Wall Street target consensus ($1.18) — Trading at $2.37 vs consensus target of $1.18, analyst downgrades (such as Barclays' Underweight) will likely drag the stock down toward fair value.
- Persistent insider selling without insider buying support — Zero insider purchases and consistent insider sales (e.g., CEO selling at $1.13 in August 2026) signal lack of management confidence in current valuation levels.
Growth Opportunities & Upside Drivers
- Consumable stream expansion from new commercial wins — The $27.1M Sampled agreement and EpiSign assay launch increase long-term SMRT cell pull-through, supporting 2028 consensus revenue estimates of $210M.
- Operating burn reduction and cost Discipline — Operating cash outflow improved from -$206.1M in 2024 to -$111.2M in 2025, slowing the cash burn rate.
- HiFi sequencing technological edge in complex diagnostics — PacBio's long-read precision offers superior structural variant detection over short-read alternatives, retaining core academic customers.
- Potential M&A target for major life science tools consolidators — A buyout by larger industry peers like Thermo Fisher or Danaher could provide floor valuation support above current market cap ($736.7M).
PACB Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About PACB (PACB)
Is PACB stock a good investment?
The cached TradeMates AI model rates PACB as AVOID with an investment score of 31/100. The model assesses PACB as an AVOID due to severe solvency risk, negative cash runway (<7 months), and a market price 100.8% above consensus target ($1.18). This is algorithmic model output, not personal investment advice.
Does PACB pay a dividend?
The cached stock data on this page does not show a positive dividend yield for PACB. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does PACB stock do?
Pacific Biosciences manufactures and sells SMRT-based long-read genetic sequencing platforms (Revio, Sequel) and short-read sequencers (Onso), earning recurring revenue from proprietary SMRT cells, reagent kits, and service agreements.
What is PACB stock's price target?
This cached page does not contain a precise model fair value for PACB.
Is PACB stock a buy?
The TradeMates model verdict for PACB is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.
Is PACB a good dividend stock?
PACB is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.